The British biotechnology startup is making "pan-gamma delta” T cell engagers it says can address the limitations of similar, existing therapies.
London, UK – May 05, 2026. Cytospire Therapeutics (‘Cytospire’), a UK based biotech developing differentiated multispecific immune cell engager antibodies designed to enhance and direct the activity ...
A laboratory study out of Roswell Park Comprehensive Cancer Center outlines a new way to boost the effectiveness of chimeric antigen receptor (CAR) T-cell therapy in solid-tumor cancers, resulting in ...
The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results